Species Differences in the Hepatobiliary Disposition and Regulation of Bile Acids
When: September 19, 2017 12:00pm CST
The disposition of bile acids in various species is governed by their physicochemical properties and carrier-mediated transport. The synthesis, metabolism, and transport of bile acids varies across species. Interpretation and extrapolation of transporter data can be complicated by species differences, leading to poor prediction of clinical effects from preclinical data. The species differences in bile acid synthesis, metabolism, transport and regulation will be discussed.
Dr. Kenneth Brouwer
Associate Dean for Research and Graduate Education, UNC Eshelman School of Pharmacy
Dr. Brouwer has over 25 years’ experience in preclinical drug development and is a co- founder of Qualyst, a provider of hepatic drug transporter products and research services. Prior to founding Qualyst, Dr. Brouwer served as Executive Director, Drug Metabolism and Pharmacokinetics at PPD Discovery, where he directed research in metabolism, pharmacokinetics, toxicology, and absorption technologies. Previously he served as Director, Preclinical Development, Drug Metabolism and Pharmacokinetics at GlaxoSmithKline and was responsible for the drug metabolism and pharmacokinetics strategy leading to candidate selection, review of candidate project plans prior to candidate selection, and developing and implementing process to ensure a smooth transition from candidate selection to full development. Dr. Brouwer has over 25 publications in peer reviewed journals, holds two patents, serves on the Editorial Advisory Board for the Journal of Pharmaceutical Sciences, and is an adjunct faculty member in the Division of Drug Delivery and Disposition at the School of Pharmacy, University of North Carolina.
Dr. Kyunghee Yang
Kyunghee Yang, Ph.D., is a scientist for DILIsym Services, Inc. and software developer working on the DILI-sim Initiative modeling team. Dr. Yang’s research focuses on the computational modeling of drug-induced liver injury (DILI) regarding interference of bile acid transport, mitochondrial dysfunction, and oxidative stress by hepatotoxic drugs.
Dr. Yang received her B.S. in pharmacy and M.S. in pharmacokinetics from Seoul National University, South Korea, and Ph.D. in Pharmaceutical Sciences from University of North Carolina at Chapel Hill. Her graduate research focused on defining the mechanisms of DILI involving the interactions in efflux of bile acids and drugs. As a result of her research, she earned numerous fellowship awards.
Dr. Yang has published scientific papers in the areas of drug metabolism and transport, regulation of drug metabolizing enzymes during pregnancy, and systems pharmacology modeling of DILI. She has been invited to speak at multiple scientific meetings including the FDA DILI Conference and ASCPT Annual Meeting. She has worked closely with the DILIsym modeling team since 2011 and joined the team in 2014.